Trial Profile
A Phase II Study of Pembrolizumab and Entinostat in Patients With Relapsed and Refractory Lymphomas
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 24 Jan 2024
Price :
$35
*
At a glance
- Drugs Entinostat (Primary) ; Pembrolizumab (Primary)
- Indications Follicular lymphoma; Hodgkin's disease
- Focus Therapeutic Use
- 19 Jan 2024 Status changed from recruiting to active, no longer recruiting.
- 12 Jun 2023 Planned End Date changed from 1 Jun 2023 to 1 Jun 2025.
- 12 Jun 2023 Planned primary completion date changed from 1 Jun 2023 to 1 Jun 2025.